ARCH:TSXV
ACHFF:OTC
Home
About us
Our story, our approach
Our Science
Pipeline, research & publications
Our Key Platforms
MetaBlok™
Treating, organ injury caused by inflammation
AB569
Treatment for Respiratory Pseudomonas aeruginosa Infections
BORG
Peptide Solid Surface Interface
MetaMx™
Brain Tumor Initiating Cell Targeting
Our Publications
Peer-reviewed scientific publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Management & lead scientists
Our Management
Governance, Executive, Board of Directors and Advisors
Our Principal Scientists
Learn about the scientists behind our technologies
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Investor relations, fundamentals
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us
Proxies and Information Circulars
Proxies and Information Circulars 2020
Download PDF Documents
Notice of Meeting and Management Information Circular
Form of Proxy
Voter Information Form
Notice and Access - Beneficial Notice
Proxies and Information Circulars 2019
Download PDF Documents
Notice of Meeting and Management Information Circular
Form of Proxy
Confirmation of Mailing
Proxies and Information Circulars 2018
Download PDF Documents
Form of Proxy 2018-03-07
Voting Instruction Form 2018-03-07
Notice of Meeting 2018-03-07
Proxies and Information Circulars 2017
Download PDF Documents
Notice of Meeting 2017-03-07
Form of Proxy 2017-03-07
Management Information Circular 2017-03-07
Voting Instruction Form 2017-03-07
Proxies and Information Circulars 2016
Download PDF Documents
Notice of Record and Meeting Dates 2016-02-01
Form of Proxy 2016-03-30
Management Information Circular 2016-03-30
Proxies and Information Circulars 2015
Download PDF Documents
Form of Proxy 2015-03-09
Management Information Circular 2015-03-09
Notice of Meeting 2015-03-09
Proxies and Information Circulars 2014
Download PDF Documents
Management Information Circular 2014-03-05
Proxies and Information Circulars 2013
Download PDF Documents
Management Information Circular 2013-03-08
Proxies and Information Circulars 2012
Download PDF Documents
Management Information Circular 2013-03-08
Recent News
May 19th 2020
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
Read More
May 8th 2020
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
Read More
See All
Subscribe to News
Proxies and Information Circulars
Home
About us
Our Science
--Our Key Platforms
---MetaBlok™
---AB569
---BORG
---MetaMx™
--Our Publications
---AB569
---Brain Tumor Stem Cell Targeting
---BORG Peptide Solid Surface Interface
---Treatments for Inflammation
Our Team
--Our Management
--Our Principal Scientists
---MetaBlok™ and MetaMx™
---AB569 & Respiratory Pseudomonas
---BORG Peptide
---Treatments for Inflammation
Investor Hub
--Fundamentals
---Press Releases
---Investor Information
---Stock Performance
--Reports and Filings
---Management Discussion and Analysis
---Annual and Quarterly Reports
---Proxies and Information Circulars
---Material Change Documents
---Other SEDAR Filings
Contact Us
Home
About us
Our Science
Our Key Platforms
MetaBlok™
AB569
BORG
MetaMx™
Our Publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Our Management
Our Principal Scientists
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us